instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy partial responder'. | Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation.
Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancer... | ERLOTINIB | DrugsGivenReaction | CC BY-NC | 34326746 | 20,854,117 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Labelled drug-drug interaction issue'. | Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.
Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests ant... | ASPIRIN, EPTIFIBATIDE, TICAGRELOR | DrugsGivenReaction | CC BY | 34327026 | 19,719,946 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary alveolar haemorrhage'. | Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.
Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests ant... | ASPIRIN, EPTIFIBATIDE, TICAGRELOR | DrugsGivenReaction | CC BY | 34327026 | 19,719,946 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary haemorrhage'. | Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.
Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests ant... | ASPIRIN, EPTIFIBATIDE, TICAGRELOR | DrugsGivenReaction | CC BY | 34327026 | 19,716,016 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.
Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests ant... | ASPIRIN, EPTIFIBATIDE, TICAGRELOR | DrugsGivenReaction | CC BY | 34327026 | 19,719,946 | 2021 |
What was the administration route of drug 'EPTIFIBATIDE'? | Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.
Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests ant... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34327026 | 19,716,016 | 2021 |
What was the outcome of reaction 'Pulmonary alveolar haemorrhage'? | Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.
Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests ant... | Recovered | ReactionOutcome | CC BY | 34327026 | 19,719,946 | 2021 |
What was the outcome of reaction 'Pulmonary haemorrhage'? | Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.
Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests ant... | Recovered | ReactionOutcome | CC BY | 34327026 | 19,716,016 | 2021 |
What was the outcome of reaction 'Thrombocytopenia'? | Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.
Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests ant... | Recovered | ReactionOutcome | CC BY | 34327026 | 19,719,946 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Treatment of Severe Hypercapnic Respiratory Failure Caused by SARS-CoV-2 Lung Injury with ECCO2R Using the Hemolung Respiratory Assist System.
Acute respiratory distress syndrome (ARDS) due to COVID-19 leads to a high rate of mortality in the intensive care unit (ICU). A lung-protective mechanical ventilation strategy ... | HEPARIN SODIUM, METHYLPREDNISOLONE ACETATE, NOREPINEPHRINE BITARTRATE, REMDESIVIR, TOCILIZUMAB | DrugsGivenReaction | CC BY | 34327027 | 19,896,123 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Treatment of Severe Hypercapnic Respiratory Failure Caused by SARS-CoV-2 Lung Injury with ECCO2R Using the Hemolung Respiratory Assist System.
Acute respiratory distress syndrome (ARDS) due to COVID-19 leads to a high rate of mortality in the intensive care unit (ICU). A lung-protective mechanical ventilation strategy ... | HUMAN PLASMA, METHYLPREDNISOLONE, NOREPINEPHRINE, REMDESIVIR, TOCILIZUMAB | DrugsGivenReaction | CC BY | 34327027 | 19,768,828 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'No adverse event'. | Treatment of Severe Hypercapnic Respiratory Failure Caused by SARS-CoV-2 Lung Injury with ECCO2R Using the Hemolung Respiratory Assist System.
Acute respiratory distress syndrome (ARDS) due to COVID-19 leads to a high rate of mortality in the intensive care unit (ICU). A lung-protective mechanical ventilation strategy ... | REMDESIVIR, TOCILIZUMAB | DrugsGivenReaction | CC BY | 34327027 | 20,932,506 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Treatment of Severe Hypercapnic Respiratory Failure Caused by SARS-CoV-2 Lung Injury with ECCO2R Using the Hemolung Respiratory Assist System.
Acute respiratory distress syndrome (ARDS) due to COVID-19 leads to a high rate of mortality in the intensive care unit (ICU). A lung-protective mechanical ventilation strategy ... | HEPARIN SODIUM, METHYLPREDNISOLONE ACETATE, NOREPINEPHRINE BITARTRATE, REMDESIVIR, TOCILIZUMAB | DrugsGivenReaction | CC BY | 34327027 | 19,896,123 | 2021 |
What was the dosage of drug 'NOREPINEPHRINE'? | Treatment of Severe Hypercapnic Respiratory Failure Caused by SARS-CoV-2 Lung Injury with ECCO2R Using the Hemolung Respiratory Assist System.
Acute respiratory distress syndrome (ARDS) due to COVID-19 leads to a high rate of mortality in the intensive care unit (ICU). A lung-protective mechanical ventilation strategy ... | 10MCG/MIN | DrugDosageText | CC BY | 34327027 | 19,768,828 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Renal tubular acidosis'. | A Rare Presentation of Checkpoint Inhibitor Induced Distal RTA.
Immune checkpoint inhibitors have opened a new era in treating advanced malignancies, resulting in a rapid increase in utilization, given the remarkable clinical outcomes. The incidence of immune-related adverse events increased due to the immunologic effe... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 34327031 | 19,716,206 | 2021 |
What was the outcome of reaction 'Renal tubular acidosis'? | A Rare Presentation of Checkpoint Inhibitor Induced Distal RTA.
Immune checkpoint inhibitors have opened a new era in treating advanced malignancies, resulting in a rapid increase in utilization, given the remarkable clinical outcomes. The incidence of immune-related adverse events increased due to the immunologic effe... | Recovering | ReactionOutcome | CC BY | 34327031 | 19,716,206 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Polyarthritis'. | Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn's Disease.
The current treatment of choice for polyarthralgia in Crohn's disease consists of disease-modifying agents and anti-inflammatory therapy, such as anti-tumor-necrosis-factor alpha inhibitors like infliximab. However, here we... | INFLIXIMAB | DrugsGivenReaction | CC BY | 34327073 | 19,678,167 | 2021-06 |
What was the outcome of reaction 'Polyarthritis'? | Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn's Disease.
The current treatment of choice for polyarthralgia in Crohn's disease consists of disease-modifying agents and anti-inflammatory therapy, such as anti-tumor-necrosis-factor alpha inhibitors like infliximab. However, here we... | Recovered | ReactionOutcome | CC BY | 34327073 | 19,678,167 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | CUPRIC CHLORIDE, DARBEPOETIN ALFA, ZINC SULFATE | DrugsGivenReaction | CC BY-NC | 34327219 | 20,058,115 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bone marrow failure'. | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | CUPRIC CHLORIDE, DARBEPOETIN ALFA, ZINC SULFATE | DrugsGivenReaction | CC BY-NC | 34327219 | 20,058,115 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ceruloplasmin decreased'. | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | CUPRIC CHLORIDE, DARBEPOETIN ALFA, ZINC SULFATE | DrugsGivenReaction | CC BY-NC | 34327219 | 20,058,115 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Copper deficiency'. | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | CUPRIC CHLORIDE, DARBEPOETIN ALFA, ZINC SULFATE | DrugsGivenReaction | CC BY-NC | 34327219 | 20,058,115 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Erythropoiesis abnormal'. | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | CUPRIC CHLORIDE, DARBEPOETIN ALFA, ZINC SULFATE | DrugsGivenReaction | CC BY-NC | 34327219 | 20,058,115 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyperzincaemia'. | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | CUPRIC CHLORIDE, DARBEPOETIN ALFA, ZINC SULFATE | DrugsGivenReaction | CC BY-NC | 34327219 | 20,058,115 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pleural effusion'. | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | CUPRIC CHLORIDE, DARBEPOETIN ALFA, ZINC SULFATE | DrugsGivenReaction | CC BY-NC | 34327219 | 20,058,115 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect decreased'. | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | CUPRIC CHLORIDE, DARBEPOETIN ALFA, ZINC SULFATE | DrugsGivenReaction | CC BY-NC | 34327219 | 20,058,115 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Upper respiratory tract infection'. | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | CUPRIC CHLORIDE, DARBEPOETIN ALFA, ZINC SULFATE | DrugsGivenReaction | CC BY-NC | 34327219 | 20,058,115 | 2021 |
What was the administration route of drug 'CUPRIC CHLORIDE'? | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34327219 | 20,058,115 | 2021 |
What was the outcome of reaction 'Copper deficiency'? | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | Recovered | ReactionOutcome | CC BY-NC | 34327219 | 20,058,115 | 2021 |
What was the outcome of reaction 'Hyperzincaemia'? | Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.
Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can ... | Recovered | ReactionOutcome | CC BY-NC | 34327219 | 20,058,115 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rhabdomyolysis'. | Recurrent Acute Kidney Injury with Severe Loin Pain and Patchy Renal Ischaemia after Anaerobic Exercise without Renal Hypouricaemia in a New Zealand European Male.
Acute kidney injury with severe loin pain and patchy renal ischaemia after anaerobic exercise (ALPE) is a rare clinical syndrome. ALPE has predominantly bee... | ACETAMINOPHEN, IBUPROFEN | DrugsGivenReaction | CC BY-NC | 34327220 | 20,122,808 | 2021 |
What was the administration route of drug 'IBUPROFEN'? | Recurrent Acute Kidney Injury with Severe Loin Pain and Patchy Renal Ischaemia after Anaerobic Exercise without Renal Hypouricaemia in a New Zealand European Male.
Acute kidney injury with severe loin pain and patchy renal ischaemia after anaerobic exercise (ALPE) is a rare clinical syndrome. ALPE has predominantly bee... | Oral | DrugAdministrationRoute | CC BY-NC | 34327220 | 20,122,808 | 2021 |
What was the outcome of reaction 'Rhabdomyolysis'? | Recurrent Acute Kidney Injury with Severe Loin Pain and Patchy Renal Ischaemia after Anaerobic Exercise without Renal Hypouricaemia in a New Zealand European Male.
Acute kidney injury with severe loin pain and patchy renal ischaemia after anaerobic exercise (ALPE) is a rare clinical syndrome. ALPE has predominantly bee... | Recovering | ReactionOutcome | CC BY-NC | 34327220 | 20,122,808 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Kidney Involvement in a Patient with AL Amyloidosis.
Antineutrophil cytoplasmic autoantibody (ANCA) vasculitis has occasionally been associated with other systemic glomerulonephritis, such as anti-glomerular basement membrane disease. Here, we report th... | BORTEZOMIB, METHYLPREDNISOLONE, PREDNISONE | DrugsGivenReaction | CC BY-NC | 34327221 | 20,203,153 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Kidney Involvement in a Patient with AL Amyloidosis.
Antineutrophil cytoplasmic autoantibody (ANCA) vasculitis has occasionally been associated with other systemic glomerulonephritis, such as anti-glomerular basement membrane disease. Here, we report th... | BORTEZOMIB | DrugsGivenReaction | CC BY-NC | 34327221 | 19,663,205 | 2021 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Kidney Involvement in a Patient with AL Amyloidosis.
Antineutrophil cytoplasmic autoantibody (ANCA) vasculitis has occasionally been associated with other systemic glomerulonephritis, such as anti-glomerular basement membrane disease. Here, we report th... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34327221 | 20,201,913 | 2021 |
What was the dosage of drug 'METHYLPREDNISOLONE'? | Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Kidney Involvement in a Patient with AL Amyloidosis.
Antineutrophil cytoplasmic autoantibody (ANCA) vasculitis has occasionally been associated with other systemic glomerulonephritis, such as anti-glomerular basement membrane disease. Here, we report th... | X3 | DrugDosageText | CC BY-NC | 34327221 | 20,201,913 | 2021 |
What was the outcome of reaction 'Acute respiratory failure'? | Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Kidney Involvement in a Patient with AL Amyloidosis.
Antineutrophil cytoplasmic autoantibody (ANCA) vasculitis has occasionally been associated with other systemic glomerulonephritis, such as anti-glomerular basement membrane disease. Here, we report th... | Fatal | ReactionOutcome | CC BY-NC | 34327221 | 19,663,205 | 2021 |
What was the outcome of reaction 'Cardiac failure'? | Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Kidney Involvement in a Patient with AL Amyloidosis.
Antineutrophil cytoplasmic autoantibody (ANCA) vasculitis has occasionally been associated with other systemic glomerulonephritis, such as anti-glomerular basement membrane disease. Here, we report th... | Fatal | ReactionOutcome | CC BY-NC | 34327221 | 19,663,205 | 2021 |
What was the outcome of reaction 'Condition aggravated'? | Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Kidney Involvement in a Patient with AL Amyloidosis.
Antineutrophil cytoplasmic autoantibody (ANCA) vasculitis has occasionally been associated with other systemic glomerulonephritis, such as anti-glomerular basement membrane disease. Here, we report th... | Fatal | ReactionOutcome | CC BY-NC | 34327221 | 20,203,153 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cytomegalovirus infection reactivation'. | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | CYCLOPHOSPHAMIDE, CYCLOSPORINE, DEXAMETHASONE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE SODIUM, PREDNISOLONE, TACROLIMUS, VALGANCICLOVIR HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC | 34327223 | 20,500,063 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic lesion'. | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | CYCLOPHOSPHAMIDE, CYCLOSPORINE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE SODIUM, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY-NC | 34327223 | 20,216,544 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Renal transplant failure'. | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | CYCLOPHOSPHAMIDE, CYCLOSPORINE, DEXAMETHASONE, EVEROLIMUS, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE SODIUM, PREDNISONE, TACROLIMUS, VALGANCICLOVIR HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC | 34327223 | 19,955,020 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Transplant rejection'. | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | CYCLOPHOSPHAMIDE, CYCLOSPORINE, GANCICLOVIR, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE SODIUM, PREDNISONE, TACROLIMUS, VALGANCICLOVIR | DrugsGivenReaction | CC BY-NC | 34327223 | 20,548,498 | 2021 |
What was the administration route of drug 'DEXAMETHASONE'? | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34327223 | 20,130,404 | 2021 |
What was the administration route of drug 'GANCICLOVIR'? | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34327223 | 20,548,498 | 2021 |
What was the administration route of drug 'PREDNISOLONE'? | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | Oral | DrugAdministrationRoute | CC BY-NC | 34327223 | 20,500,063 | 2021 |
What was the administration route of drug 'PREDNISONE'? | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | Oral | DrugAdministrationRoute | CC BY-NC | 34327223 | 20,216,544 | 2021 |
What was the outcome of reaction 'Cytomegalovirus infection'? | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | Recovered | ReactionOutcome | CC BY-NC | 34327223 | 20,216,544 | 2021 |
What was the outcome of reaction 'Metabolic acidosis'? | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | Not recovered | ReactionOutcome | CC BY-NC | 34327223 | 20,548,498 | 2021 |
What was the outcome of reaction 'Pancytopenia'? | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | Not recovered | ReactionOutcome | CC BY-NC | 34327223 | 20,548,498 | 2021 |
What was the outcome of reaction 'Pulmonary cavitation'? | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | Not recovered | ReactionOutcome | CC BY-NC | 34327223 | 20,548,498 | 2021 |
What was the outcome of reaction 'Renal failure'? | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | Not recovered | ReactionOutcome | CC BY-NC | 34327223 | 20,548,498 | 2021 |
What was the outcome of reaction 'Transplant rejection'? | Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic disease... | Not recovered | ReactionOutcome | CC BY-NC | 34327223 | 20,548,498 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
BACKGROUND
Among locally advanced gastric cancer (LAGC) patients, poor response to initial neoadjuvant chemotherapy (NAC) is associated with unfavorable outcomes; however, changing the postoperative therapy regimen ... | CAPECITABINE, CISPLATIN, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 34327603 | 20,181,045 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal disorder'. | Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
BACKGROUND
Among locally advanced gastric cancer (LAGC) patients, poor response to initial neoadjuvant chemotherapy (NAC) is associated with unfavorable outcomes; however, changing the postoperative therapy regimen ... | CAPECITABINE, CISPLATIN, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 34327603 | 20,181,045 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatotoxicity'. | Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
BACKGROUND
Among locally advanced gastric cancer (LAGC) patients, poor response to initial neoadjuvant chemotherapy (NAC) is associated with unfavorable outcomes; however, changing the postoperative therapy regimen ... | CAPECITABINE, CISPLATIN, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 34327603 | 20,181,045 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukopenia'. | Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
BACKGROUND
Among locally advanced gastric cancer (LAGC) patients, poor response to initial neoadjuvant chemotherapy (NAC) is associated with unfavorable outcomes; however, changing the postoperative therapy regimen ... | CAPECITABINE, CISPLATIN, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 34327603 | 20,181,045 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neurotoxicity'. | Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
BACKGROUND
Among locally advanced gastric cancer (LAGC) patients, poor response to initial neoadjuvant chemotherapy (NAC) is associated with unfavorable outcomes; however, changing the postoperative therapy regimen ... | CAPECITABINE, CISPLATIN, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 34327603 | 20,181,045 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
BACKGROUND
Among locally advanced gastric cancer (LAGC) patients, poor response to initial neoadjuvant chemotherapy (NAC) is associated with unfavorable outcomes; however, changing the postoperative therapy regimen ... | CAPECITABINE, CISPLATIN, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 34327603 | 20,181,045 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Crohn^s disease'. | Atypical HUS and Crohn's disease-interference of intestinal disease activity with complement-blocking treatment.
In atypical hemolytic-uremic syndrome (aHUS), various defects of the complement system have been reported to explain pathophysiology. Therapeutic options for complement inhibition are well-recognized; howeve... | ECULIZUMAB | DrugsGivenReaction | CC BY | 34328541 | 19,662,173 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug level decreased'. | Atypical HUS and Crohn's disease-interference of intestinal disease activity with complement-blocking treatment.
In atypical hemolytic-uremic syndrome (aHUS), various defects of the complement system have been reported to explain pathophysiology. Therapeutic options for complement inhibition are well-recognized; howeve... | ECULIZUMAB | DrugsGivenReaction | CC BY | 34328541 | 19,662,173 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Total complement activity increased'. | Atypical HUS and Crohn's disease-interference of intestinal disease activity with complement-blocking treatment.
In atypical hemolytic-uremic syndrome (aHUS), various defects of the complement system have been reported to explain pathophysiology. Therapeutic options for complement inhibition are well-recognized; howeve... | ECULIZUMAB | DrugsGivenReaction | CC BY | 34328541 | 19,662,173 | 2021-10 |
What was the outcome of reaction 'Crohn^s disease'? | Atypical HUS and Crohn's disease-interference of intestinal disease activity with complement-blocking treatment.
In atypical hemolytic-uremic syndrome (aHUS), various defects of the complement system have been reported to explain pathophysiology. Therapeutic options for complement inhibition are well-recognized; howeve... | Recovering | ReactionOutcome | CC BY | 34328541 | 19,662,173 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Angioedema'. | DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema.
The patient is a 69-year-old male with a past medical history of intellectual disability, hypertension, type 2 diabetes mellitus, and angiotensin-converting enzyme (ACE) inhibitor-associated angioedema who presented to the... | SITAGLIPTIN PHOSPHATE | DrugsGivenReaction | CC BY-NC | 34330175 | 20,176,360 | 2021 |
What was the administration route of drug 'SITAGLIPTIN PHOSPHATE'? | DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema.
The patient is a 69-year-old male with a past medical history of intellectual disability, hypertension, type 2 diabetes mellitus, and angiotensin-converting enzyme (ACE) inhibitor-associated angioedema who presented to the... | Oral | DrugAdministrationRoute | CC BY-NC | 34330175 | 20,176,360 | 2021 |
What was the outcome of reaction 'Angioedema'? | DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema.
The patient is a 69-year-old male with a past medical history of intellectual disability, hypertension, type 2 diabetes mellitus, and angiotensin-converting enzyme (ACE) inhibitor-associated angioedema who presented to the... | Recovered | ReactionOutcome | CC BY-NC | 34330175 | 20,176,360 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal pain'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN, CEFTRIAXONE, CITALOPRAM HYDROBROMIDE, METRONIDAZOLE, PIPERACILLIN SODIUM\TAZOBACTAM SODIUM, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute myocardial infarction'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN, CEFTRIAXONE, CITALOPRAM HYDROBROMIDE, METRONIDAZOLE, PIPERACILLIN SODIUM\TAZOBACTAM SODIUM, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Alanine aminotransferase increased'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN CALCIUM, CITALOPRAM HYDROBROMIDE, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,758,979 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chest pain'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN, CEFTRIAXONE, CITALOPRAM HYDROBROMIDE, METRONIDAZOLE, PIPERACILLIN SODIUM\TAZOBACTAM SODIUM, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cholestasis'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN CALCIUM, CITALOPRAM HYDROBROMIDE, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,758,979 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Coronary artery dissection'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN, CEFTRIAXONE, CITALOPRAM HYDROBROMIDE, METRONIDAZOLE, PIPERACILLIN SODIUM\TAZOBACTAM SODIUM, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Flank pain'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN, CEFTRIAXONE, CITALOPRAM HYDROBROMIDE, METRONIDAZOLE, PIPERACILLIN SODIUM\TAZOBACTAM SODIUM, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypersensitivity'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN CALCIUM, CITALOPRAM HYDROBROMIDE, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,758,979 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukocytosis'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN, CEFTRIAXONE, CITALOPRAM HYDROBROMIDE, METRONIDAZOLE, PIPERACILLIN SODIUM\TAZOBACTAM SODIUM, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malaise'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN, CEFTRIAXONE, CITALOPRAM HYDROBROMIDE, METRONIDAZOLE, PIPERACILLIN SODIUM\TAZOBACTAM SODIUM, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Muscular weakness'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN, CEFTRIAXONE, CITALOPRAM HYDROBROMIDE, METRONIDAZOLE, PIPERACILLIN SODIUM\TAZOBACTAM SODIUM, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myalgia'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN, CEFTRIAXONE, CITALOPRAM HYDROBROMIDE, METRONIDAZOLE, PIPERACILLIN SODIUM\TAZOBACTAM SODIUM, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Urinary tract infection'. | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | ASPIRIN, ATORVASTATIN CALCIUM, CITALOPRAM HYDROBROMIDE, RAMIPRIL | DrugsGivenReaction | CC BY | 34330325 | 19,758,979 | 2021-07-30 |
What was the administration route of drug 'CEFTRIAXONE'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Intramuscular | DrugAdministrationRoute | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
What was the administration route of drug 'METRONIDAZOLE'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Endocervical | DrugAdministrationRoute | CC BY | 34330325 | 20,230,163 | 2021-07-30 |
What was the dosage of drug 'CEFTRIAXONE'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | UNK (SINGLE DOSE) | DrugDosageText | CC BY | 34330325 | 19,732,155 | 2021-07-30 |
What was the outcome of reaction 'Abdominal pain'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
What was the outcome of reaction 'Acute myocardial infarction'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
What was the outcome of reaction 'Alanine aminotransferase increased'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,758,979 | 2021-07-30 |
What was the outcome of reaction 'Chest pain'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
What was the outcome of reaction 'Cholestasis'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,758,979 | 2021-07-30 |
What was the outcome of reaction 'Coronary artery dissection'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
What was the outcome of reaction 'Drug reaction with eosinophilia and systemic symptoms'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,774,577 | 2021-07-30 |
What was the outcome of reaction 'Drug-induced liver injury'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,774,577 | 2021-07-30 |
What was the outcome of reaction 'Eosinophil count increased'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,758,979 | 2021-07-30 |
What was the outcome of reaction 'Eosinophilia'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,709,680 | 2021-07-30 |
What was the outcome of reaction 'Flank pain'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
What was the outcome of reaction 'Hepatic enzyme increased'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,758,979 | 2021-07-30 |
What was the outcome of reaction 'Leukocytosis'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
What was the outcome of reaction 'Malaise'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
What was the outcome of reaction 'Muscular weakness'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
What was the outcome of reaction 'Myalgia'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
What was the outcome of reaction 'Pyrexia'? | Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms.
BACKGROUND
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and... | Recovered | ReactionOutcome | CC BY | 34330325 | 19,736,183 | 2021-07-30 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.